India, Sept. 21 -- The following biotech stocks reached a 52-week high on September 18, 2026, driven by the gain on certain clinical trial results or an announced public offering.
Vogenx Inc. (VOGX) Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics to treat metabolic diseases.On Friday, shares surged to a 52-week high of $38.41. Vogenx debuted on the Nasdaq Capital Market on August 12, 2026, and commenced trading with an initial public offering (IPO) of 6,250,000 shares of common stock at $13 per share. The company gained about $81.3 million from the IPO. Mizagliflozin is the company's lead product candidate and is currently being advanced for the treatment of post-bariatric...